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Abstract
Background: Antimicrobial resistance (AMR) is a prominent threat to public health. Although many guidelines have
been developed over the years to tackle this issue, their impact on health care practice varies. Guidelines are often
based on evidence from clinical trials, but these have limitations, particularly in the breadth and generalisability of
the evidence and evaluation of the guidelines’ uptake. The aim of this study was to investigate how national and
local guidelines for managing common infections are developed and explore guideline committee members’
opinions about using real-world observational evidence in the guideline development process.
Methods: Six semi-structured interviews were completed with participants who had contributed to the
development or adjustment of national or local guidelines on antimicrobial prescribing over the past 5 years (from
the English National Institute for Health and Care Excellence (NICE)). Interviews were audio recorded and
transcribed verbatim. Data was analysed thematically. This also included review of policy documents including
guidelines, reports and minutes of guideline development group meetings that were available to the public.
Results: Three key themes emerged through our analysis: perception versus actual guideline development process,
using other types of evidence in the guideline development process, and guidelines are not enough to change
antibiotic prescribing behaviour. In addition, our study was able to provide some insight between the documented
and actual guideline development process within NICE, as well as how local guidelines are developed, including
differences in types of evidence used.
Conclusions: This case study indicates that there is the potential for a wider range of evidence to be included as
part of the guideline development process at both the national and local levels. There was a general agreement
that the inclusion of observational data would be appropriate in enhancing the guideline development process, as
well providing a potential solution for monitoring guideline use in clinical practice, and improving the
implementation of treatment guidelines in primary care.
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Background
Evidence-based medicine (EBM) has been one of the de-
fining features of health care policy and practice since the
1990s. The evidence base for clinical decision-making is
built upon critical assessment of relevant literature and as-
sessment of the strength of scientific evidence to inform
clinical practice along with clinical reasoning [1, 2]. Clin-
ical practice guidelines, hereafter referred to as guidelines,
have formed a cornerstone of the translation of EBM into
practice. The route from scientific literature to a new or
updated guideline passes through the development of as-
sessments of evidence by a group of guideline committee
members and experts in a medical topic. This process of
development of guidelines is not straightforward and has
been characterised as a ‘black box’ [2]. In developing
guidelines, other decisive factors have been identified that
play a role alongside the ‘robustness’ of scientific evidence,
such as reasoning based on practical or political reper-
toires [3] and views from members of guideline develop-
ment groups [2]. The guideline committee members who
develop and adapt a guideline, thus develop and adapt
guidelines based on a variety of sources, over and above
the available evidence. This differs to EBM where other
types of studies, such as cohort and case-control studies
may also be considered [1].
Since 1999, National Institute for Health and Care Ex-
cellence (NICE) role is to improve outcomes for people
using the National Health Service (NHS) and other public
health and social care services. NICE do this through: pro-
ducing evidence-based guidance and advice for health,
public health and social care practitioners; developing
quality standards and performance metrics for those pro-
viding and commissioning health, public health and social
care services; and, providing a range of information ser-
vices for commissioners, practitioners and managers
across the spectrum of health and social care [4].
Although many guidelines have been developed over
the years, their impact on health care practice varies [5].
The acceptance [6] and particularly the implementation
of guidelines by doctors, other health care practitioners,
and administrators often remain low [7, 8]. Many rea-
sons for guidelines not being adopted and implemented
have been brought forward. These include social and
political processes, factors relating to health care profes-
sionals, factors relating to patients, and factors relating
to the guideline itself [6, 9]. To bring best evidence into
best practice, improvements in each of these domains
are necessary [8]. Guideline development and adaptation
in particular appear to be important intervention points
for improving the implementability of guidelines [10].
The usability and implementability of guidelines can
be improved by broadening the evidence base, and by
bringing the evidence that is used and clinical practice
closer together [11]. In identifying evidence to inform
the development and adaptation of guidelines, prefer-
ence is often given to randomized clinical trial (RCT)
data. RCTs give valuable insight into the effectiveness of
medications and other treatments. However, patient
populations in these studies are often small with limited
follow-up, and as RCTs are often costly to conduct, they
cannot always be reproduced in all local circumstances.
Moreover, by definition the patients included in RCTs
conform to multiple inclusion criteria. In many cases
there is little evidence on a sizeable group of patients
who do not conform to the inclusion criteria of the stud-
ies used, or patients in various countries and settings
[12]. Furthermore, evidence from RCTs is often summa-
rized in systematic reviews, which may make the pres-
ence or absence of diversity in the included patient
populations less apparent. In clinical practice, patient
populations are far more diverse than participants in
RCTs, which complicates the task of finding applicable
and rigorous evidence [13]. The use of a broader evi-
dence base in guideline development and adaptation has
therefore been advocated to reduce the gap between
evidence and practice.
Use of evidence that identifies a patient’s risk of devel-
oping a disease is highly relevant for identifying patient
groups that need to be targeted with treatment. This
type of data analysis, however, cannot be captured in
clinical trial-derived evidence, as this needs incorpor-
ation of data about variability within a population. In
guidelines on the prevention of cardiovascular events,
evidence on identifying patients’ risk of a cardiovascular
event has been incorporated [14, 15]. However, other
guidelines to date have not made use of such types of
evidence [16]. One of the factors contributing to this
may be that standards for assessing the quality of risk
data analytics have not been developed to the same
scientific rigour as standards for incorporating more
traditional types of evidence [10]. Therefore, interpretation
of this evidence is often left up to the interpretation of indi-
vidual guideline development group members and group
processes [2], which appears to lead few groups to use this
evidence. However, incorporating risk based analyses is par-
ticularly necessary in guidelines aimed at types of health
care that are not specific to one diagnosis and that require
complex decisions by health care practitioners [13].
Relevance of guidelines in prescribing practices in
primary care
In primary care, the prescription of antibiotics leads to
discomfort in decision-making [17], due to a large degree
of diagnostic uncertainty [18]. Such decisions, moreover,
occur frequently in primary care practices, as patients often
attend their General Practitioner (GP) with symptoms such
as acute sore throat [19] or acute cough [20, 21], for which
antibiotic treatment is one of the available options. Previous
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studies have shown that antibiotic treatment for acute sore
throat is effective when a bacterial infection is present [22].
However, patients with a low risk of complications from
the infection are likely to gain only a small benefit from tak-
ing antibiotics. At the same time, rising concerns about
antimicrobial resistance lead to the need to diminish anti-
biotic use [23]. Antibiotic prescribing, then, needs to be
targeted foremost at patient groups who are most in need
of them, that is, patients who are at high risk of developing
infection-related complications.
Prescribing behaviours appear to be based on symptoms
rather than on an assessment of the risks to the patient, as
the latter is often unclear to GPs [19]. Incorporating evi-
dence about the risks to patients of complications relating
to an infection, or relating to the use of common treat-
ments such as antibiotics could facilitate and improve
decision-making in primary care [20, 21]. At present, more-
over, it is unclear whether antibiotic prescribing decisions
are based on the use of guidelines [18]. More intelligent im-
plementation strategies for antibiotic prescribing guidelines
have been called for [24]. Thus, there is a need for bringing
more clinically relevant evidence into guidelines to improve
their uptake by GPs.
The aim of this study was to investigate how national
and local guidelines for managing common infections are
developed and explore guideline committee members’
opinions about using real-world observational evidence in
the guideline development process.
Methods
This case study is based on interviews with guideline de-
velopers involved in the creation of national and/or local
guidelines for antimicrobial prescribing, as well as on a
documentary analysis of existing national and local guide-
line information. Data were collected between September
2018 and March 2019.
Data collection
Research team members from the Health E-Research
Centre at the University of Manchester conducted six
semi-structured face-to-face interviews were conducted
with participants who had contributed to the develop-
ment or adjustment of national or local guidelines on
antimicrobial prescribing over the past 5 years. The national
guidelines were developed by the NICE in England. Inter-
views focused on the types of evidence used in the guideline
development process and potential challenges in changing
prescribing behaviour for treating common infections. An
interview guide was developed to explore and capture guide-
line developers’ experiences and opinions regarding the how
evidence was chosen and the challenges of incorporating
other forms of evidence within the development process.
The interview guide also included three vignettes that
were developed by the research team: the first vignette
presented two published research studies. Both studies
gave information about two different types of scoring
tools for diagnosing sore throat in clinical practice;
guidelines recommended the clinical use of these tools
[25, 26]. The second vignette presented data from the
Clinical Practice Research Datalink (CPRD), which consists
of anonymized patient records from over 400 primary care
practices in England that were linked to hospital admission
records. CPRD data was then compared with antibiotic
prescribing data for acute sore throat from a recently pub-
lished study [25] that compared different antibiotic pre-
scribing strategies in order to explore the generalisability of
this study. The third vignette showed three figures based
on CPRD data: the first showed the variability of GP anti-
biotic prescribing for sore throat (or Upper Respiratory
Tract Infection (URTI)) since the year 2000; the second
showed average prescribing rates for each year with the
three main changes in the rate of prescribing indicated in
red; and the third figure showed average prescribing rates
for each year with yellow lines indicating the changing/up-
dating of guidelines and red lines indicated the three main
changes in the rate of prescribing. The third vignette was
presented in order to explore the (lack of) changes in pri-
mary care antibiotic prescribing despite the introduction of
several guidelines.
Interviews lasted between 45 to 90min. They were
audio-recorded and transcribed verbatim, with respon-
dents then sent a copy of the transcript to review and
make any necessary amendments. In addition to the in-
terviews, policy documents including guidelines, reports
and minutes of guideline development group meetings,
were collected from NICE and the Greater Manchester
Clinical Standards Board. Where scientific evidence was
cited in these guidelines, this was also collected. All in-
formation was drawn from publically available data.
Data analysis
Thematic analysis was used to analyse interview and
document data [27]. Thematic analysis is a widely used
method to identify, organise, analyse and report patterns
or themes within qualitative research data. Themes were
compared across participants and documents. Data ana-
lysis took place alongside data collection, in order to en-
sure that emerging themes from the preliminary analysis
will sensitize the researcher to important topics during
the interviews, and to ensure that an appropriate assess-
ment of data saturation could be made. NVivo 11 (QSR
International Pty Ltd., 2014) was used to aid in data
management and analysis.
Ethical considerations
Participation in the study was based on informed consent
and was voluntary. All participants received a participant
information sheet and were asked to sign a consent form
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prior to starting the interview. This study received ethics
approval from the University of Manchester Research Eth-
ics committee, Manchester, U.K (Ref: 2018–4682-6712).
Results
Three key themes emerged through our study: 1) Percep-
tion versus actual guideline development process, 2) Using
other types of evidence in the guideline development
process, and 3) Guidelines are not enough for changing
antibiotic prescribing behaviour. Quotes from participants
are used to exemplify and clarify themes. Due to under-
recruitment to the study and to further ensure participant
anonymity, no further information regarding participant
characteristics will be given.
Theme 1: perception versus actual guideline development
process
Whilst publicly available documents gave a general over-
view of the process involved for developing national
guidelines, the interviews provided a more detailed de-
scription of the methods used and who was involved
throughout the process. In particular, a difference was
noted in some areas of the guideline development process,
with the majority of the work undertaken by staff at NICE
and limited input from committee members and other
stakeholders. Several participants described how sugges-
tions made to NICE, such as including expert opinions
and a wider range of evidence were considered but not
acted upon, preferring to focus efforts on the literature.
Whilst all participants reflected that they understood why
this was the process, several felt that there was a lot of
value in speaking with experts with extensive clinical
knowledge and practice.
“They [NICE] are just concentrating on systematic
reviews. And, especially with something like this, the
antibiotic guidance, which is so broad, there’s a huge
quantity of experience out there that they could ask about
for each of the different guidance. I’ve said each time, for
each one, they ought to get other people involved.”
The guideline development process for developing guide-
lines at the local level was not well documented, with
documentation published online for the year 2017 to 2018
only. As a result, interviews with participants who contrib-
uted to local guideline development provided useful insight
in this area. Participants were able to describe a clear dif-
ference between national and local guideline development.
Locally, an emphasis was placed on ensuring that local
contexts and issues were built into the guidelines whilst
cross-referencing national guidelines. Participants involved
in the development of local guidelines discussed how local
practitioners were encouraged to raise issues they had en-
countered when treating patients to ensure that these
could be addressed in updated guidelines to ensure practi-
tioners felt confident in their practice. As a result, guide-
lines are updated to reflect these issues and any other
localised/national changes every quarter.
Theme 2: using other types of evidence in the guideline
development process
All participants felt that a much wider range of evidence
should be used in national guideline development, rather
than relying on systematic literature reviews and RCTs
that met strict criteria as set out by NICE. Several partic-
ipants commented that some of the studies reviewed in
the national guideline process were difficult to generalise
to the U.K population because they were either a sys-
tematic literature review or the RCT was conducted in a
very specific type of population or in a different country.
Whilst some participants were able to reflect as to the
rational for why NICE restrict their studies to systematic
literature reviews and RCTs, all participants noted that
other studies that provided evidence for best antibiotic
prescribing behaviour using other research methods were
being excluded (such as qualitative research and observa-
tional studies). Many felt that given the current urgency to
address antibiotic resistance, there was the potential that
other types of studies, such as a qualitative study, could
provide useful insight into prescribing behaviours that
could then be considered in guideline development.
“They have a very strict criteria about what guidance
they use, and it’s on a hierarchical basis. So, they,
basically, will use a systematic review, if that’s
available of the area, and then if there aren’t any
systematic reviews they will go to RCTs. But, they
would not go to RCTs if there was a good systematic
review. And then, they really very rarely go anywhere
else for any other information. I think they should use
qualitative evidence, as well, because I think that’s
really useful and it gives you more valuable insight
into how things work in real life, which you don’t get
with a RCT or systematic review.”
The interview included asking participants a series of
questions based on three vignettes. Vignette one pre-
sented two published research studies. Both studies gave
information about two different types of scoring tools
for sore throat. Nearly all participants were familiar with
the scoring tools presented which prompted discussions
around how such scoring tools can be useful in clinical
practice to support decision making. Despite the limita-
tions of the first scoring tool, the majority of participants
felt that having some form of tool to use in clinical prac-
tice was better than having none at all. Some partici-
pants who were familiar with the second study noted
that whilst this was a more appropriate study to consider
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as it was conducted in the U.K compared to the first
scoring tool that was developed in the U.S; this study
did not meet the NICE requirements for inclusion in the
guideline development process. Despite its limitations,
some felt it was a missed opportunity for a recently U.K
developed scoring tool to be included in the NICE
guideline development process.
Moving through the first vignette, participants tended to
focus on the table of information which presented the pre-
dictive value of bacterial clinical scoring methods for
complication, describing how useful it was to see the data
presented for each study side by side. Participants indi-
cated that presenting all results in this manner during the
guideline development process would be more useful.
Vignette two presented compared UK primary care
CPRD data on antibiotic prescribing for acute sore throat
to a recently published study that compared different anti-
biotic prescribing strategies. Nearly all participants noted
how interesting it was to see the research study data
presented side by side with population data. In particular,
being able to see the study data with the corresponding
CPRD data made participants feel more confident in inter-
preting the results of published studies, as well as provid-
ing additional evidence that could assist in determining
whether specific interventions could be generalised to the
U.K population. All participants felt that having study re-
sults presented alongside the relevant population dataset
would be beneficial in future guideline development.
“It’s really interesting to see the study compared with the
population. Reading the study, I felt it was as
representative as you could get in general practice, but
seeing it here with CPRD data is very beneficial because
RCTs tend to have a particular type of population which
might not represent Wigan. It just makes you feel a bit
more confident in the published stuff.”
In discussing the third vignette, most participants
found the third figure within the vignette to be the most
useful. The third figure shows average prescribing rates
for each year with yellow lines indicating the changing/
updating of guidelines and red lines indicated the three
main changes in the rate of prescribing. Participants
noted how the combination of information was comple-
mentary, with several suggesting the addition of key flu
outbreaks (such as Swine Flu) labelled would make this
figure even more valuable, particularly in monitoring
antibiotic prescribing over time using local data.
“Things like if you’re looking at something like
antimicrobial prescribing, it would be useful to see when
there were bad years for flu, like swine flu…when those
happened and what the knock-on impact of that was, you
know, other outbreak kind of related stuff. When there
were…I don’t know whether…if there’s a really bad
winter, does that make a bigger impact on antibiotic use
in terms of more transmission of…you know, is there more
transmission of upper respiratory tract infections, things
like that. I know obviously the flu does have an impact, so
that would be useful to see in the data.”
Theme 3: guidelines are not enough for changing
antibiotic prescribing behaviour
Opinions about the usefulness and effectiveness of na-
tional guidelines for antibiotic prescribing varied. All
participants stated that they were aware of current gov-
ernmental policies and guidelines aimed at reducing
antibiotic prescribing. However, participants involved in
some form of clinical practice admitted to rarely using
national guidelines in practice, relying more on the ex-
pertise of other clinical professionals, their own clinical
knowledge or a combination of locally produced guide-
lines and expert knowledge. Most participants stated
there were other guidelines for antibiotic prescribing
that were more useful to prescribing practitioners on a
day-to-day basis. Participants commonly referred to the
guidelines produced by Public Health England and lo-
cally produced guidelines when asked what other types
of guidelines either they themselves used or their col-
leagues used in practice. In describing what they felt was
more useful about these other guidelines; participants
noted the usefulness of having information presented in
a tabulated format on the different types of antibiotics
for a range of health conditions.
All participants noted that changes and updates to NICE
antibiotic prescribing does not necessarily result in reduc-
tions in antibiotic prescribing. There was a mixed response
as to whether GP’s were monitored on their prescribing be-
haviour. Regional variations were noted in how antibiotic
prescribing was monitored. It was noted that some local
Clinical Commissioning Groups (CCGs that are organisa-
tions responsible for the planning and commissioning of
health care in a region) were more proactive than others,
whilst other CCGs did not have the capacity to provide
additional support to GPs in reducing prescribing behav-
iours. Financial incentives were deemed not to work as they
were too negligible to make a difference to prescribing be-
haviours, particularly those who work in high prescribing
areas. One suggestion was to have localised targets that
were attainable, rather than a national target.
“They’re quite strange targets really because they’re
arbitrary, and based on an England mean from 2013.
It doesn’t account for anything that’s issued from walk-
in centres, out-of-hours places that use different
budgets and private prescriptions, which in affluent
areas, GPs might offer both. So if you’re not going to
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make it, it’s not an incentive to reduce your prescribing
behaviour. Plus there’s no penalty and the financial
incentive isn’t worth it if you’re already struggling to
meet that target. What we should do is have more
localised targets that address the contexts we work
in…that way if becomes more like comparing apples
with apples, rather than apples with pears.”
Another issue that was raised by participants was that
national guidelines do not take into account the local-
ised contexts, such as areas with a higher rate of elderly
patients, which often results in higher rates of prescrib-
ing. Many felt that as a result of this, many GPs and
other forms of prescribers simply did not bother to look
at the NICE guidelines, preferring to use more localised
versions that provided recommendations specific to the
populations that they worked with. In addition, several
participants highlighted that prescribing data did not ne-
cessarily represent prescribing behaviour, particularly if
GPs offer private prescriptions.
Several participants reflected on the pressures that GPs
face in seeing a patient within a 10-min appointment slot.
It was suggested that providing GPs with additional sup-
port (such as mentoring), regular meetings to discuss diffi-
cult cases and learning from others in how they have able
to tackle these types of cases, as well as a forum to discuss
guidelines/new regulations, were key to reducing anti-
biotic prescribing in GPs. At the same time, participants
who discussed these issues also noted the importance of
sharing the responsibility with the public, rather than it
being the sole responsibility of the GP or healthcare prac-
titioner. Suggestions were made for the Government to
provide more public health education campaigns to the
general public, with targeted approaches to population
groups who may insist on being given antibiotics when
there is not a medical need.
Discussion
Although many guidelines have been developed over the
years, particularly on managing common infections, their
impact on health care practice varies. Treatment guidelines
are often based on assessments of evidence from clinical tri-
als or systematic literature reviews, but these have limita-
tions, particularly in representing the whole population of
patients in primary care. This suggests that there is a need
for bringing more clinically relevant evidence into guide-
lines to improve their uptake in clinical practice.
This case study provides an in-depth look at the guideline
development process within treating common infections,
the challenges of reducing antibiotic prescribing that go
beyond the guideline process and how other forms of
evidence could be utilised in the guideline development
process. Three key themes emerged through our study: 1)
Perception versus actual guideline development process, 2)
Using other types of evidence in the guideline development
process, and 3) Guidelines are not enough for changing
antibiotic prescribing behaviour. In addition, our study was
able to provide some insight between the documented and
actual guideline development process within NICE, as well
as how local guidelines are developed.
Whilst discussing other types of evidence, such as the
availability of population data, all participants stated that
they would welcome additional evidence that provides
them with relevant population data that could be pre-
sented alongside the results of published studies. In
addition, interview participants were able to reflect on the
constraints imposed onto NICE in the guideline develop-
ment process by other stakeholders within government.
NICE guidelines make evidence-based recommenda-
tions on a wide range of topics, from preventing and
managing specific conditions, improving health and
managing medicines in different settings, to providing
social care to adults and children, and planning broader
services and interventions to improve the health of com-
munities [4]. However, implementing these guidelines in
practice is not without its challenges when GPs also have
to meet other Quality Improvement and Quality Assur-
ance targets.
It has been recommended that in order to be used,
clinical guidelines need to be integrated as part of other
healthcare quality improvement processes [13, 28]. This
will require cooperation between guideline developers
and other healthcare stakeholders [13, 29], similar to the
types of working that were noted in our study at the
local guideline develop level. This strategy has been
found to be successful elsewhere. For example, Richter-
Sundberg et al. (2015) found that it was possible for the
planning and development of guidelines to involved na-
tional, regional and local health care providers. Despite
the additional time required to utilise such a develop-
ment process, particularly given the complexities con-
nected to different guideline areas, time and resources
available, having a dialogue and making agreements with
stakeholders at all levels was found to be valuable.
Our results are based on a single case study of com-
mon infection guideline development with an emphasis
on antibiotic prescribing. There might be other aspects
that need to be considered in other contexts and other
ways of achieving reduced levels of antibiotic prescribing
in primary care clinical practice. On a more practical
level, regular meetings between local and national guide-
line developers would provide insight into the different
patient groups across the U.K and the difficulties of
utilising national guidelines in a range of population
settings. In addition, further consideration could be
given to utilising complementary local data to monitor
the effectiveness of local interventions, which could then
be considered at the local guideline level.
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Conclusion
This case study has provided insight into the processes for
antimicrobial guideline development at the national and
local levels in the U.K, particularly in the types of evidence
that are currently used. The study has indicated that
guideline developers could benefit from including a wider
range of published research studies, as well as the input
from experts during the early stages of developing or up-
dating antibiotic prescribing guidelines. In addition, the
inclusion of population data was found to be a source of
evidence that many guideline developers would like to see
utilised as part of the wider range of evidence presented to
them. However, there will be other aspects that need to be
considered in using other forms of evidence within the
process of developing guidelines, as well as in how these
are used for monitoring purposes. Furthermore, Govern-
ment and guideline developers will also need to consider
focusing on addressing the wider issues that can impact
antibiotic prescribing and ensure that the necessary re-
sources and support are put in place for both GPs and the
general public to achieve rational antibiotic prescribing.
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